These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 32226538)

  • 21. Curcumin analogue UBS109 prevents bone loss in breast cancer bone metastasis mouse model: involvement in osteoblastogenesis and osteoclastogenesis.
    Yamaguchi M; Zhu S; Zhang S; Wu D; Moore TM; Snyder JP; Shoji M
    Cell Tissue Res; 2014 Jul; 357(1):245-52. PubMed ID: 24723227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hydrogen sulphide-releasing diclofenac derivatives inhibit breast cancer-induced osteoclastogenesis in vitro and prevent osteolysis ex vivo.
    Frantzias J; Logan JG; Mollat P; Sparatore A; Del Soldato P; Ralston SH; Idris AI
    Br J Pharmacol; 2012 Mar; 165(6):1914-1925. PubMed ID: 21955294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zerumbone abolishes RANKL-induced NF-kappaB activation, inhibits osteoclastogenesis, and suppresses human breast cancer-induced bone loss in athymic nude mice.
    Sung B; Murakami A; Oyajobi BO; Aggarwal BB
    Cancer Res; 2009 Feb; 69(4):1477-84. PubMed ID: 19190327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pentamidine Inhibits Titanium Particle-Induced Osteolysis
    Ihn HJ; Kim K; Cho HS; Park EK
    Tissue Eng Regen Med; 2019 Jun; 16(3):265-273. PubMed ID: 31205855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Morusin inhibits breast cancer-induced osteolysis by decreasing phosphatidylinositol 3-kinase (PI3K)-mTOR signalling.
    Zhang L; Li W; Chen X; Cao D; You S; Shi F; Luo Z; Li H; Zeng X; Song Y; Li N; Akimoto Y; Rui G; Chen Y; Wu Z; Xu R
    Chem Biol Interact; 2024 May; 394():110968. PubMed ID: 38522564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.
    Strazic-Geljic I; Guberovic I; Didak B; Schmid-Antomarchi H; Schmid-Alliana A; Boukhechba F; Bouler JM; Scimeca JC; Verron E
    Biochem Pharmacol; 2016 Sep; 116():11-21. PubMed ID: 27378505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
    Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
    J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
    Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
    Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IL-11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cells.
    McCoy EM; Hong H; Pruitt HC; Feng X
    BMC Cancer; 2013 Jan; 13():16. PubMed ID: 23311882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.
    Canon JR; Roudier M; Bryant R; Morony S; Stolina M; Kostenuik PJ; Dougall WC
    Clin Exp Metastasis; 2008; 25(2):119-29. PubMed ID: 18064531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platycodin D Blocks Breast Cancer-Induced Bone Destruction by Inhibiting Osteoclastogenesis and the Growth of Breast Cancer Cells.
    Lee SK; Park KK; Kim HJ; Kim KR; Kang EJ; Kim YL; Yoon H; Kim YS; Chung WY
    Cell Physiol Biochem; 2015; 36(5):1809-20. PubMed ID: 26184636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The inhibitory effect of roasted licorice extract on human metastatic breast cancer cell-induced bone destruction.
    Lee SK; Park KK; Park JH; Lim SS; Chung WY
    Phytother Res; 2013 Dec; 27(12):1776-83. PubMed ID: 23401151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
    Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
    Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
    Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
    Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.
    Logan JG; Sophocleous A; Marino S; Muir M; Brunton VG; Idris AI
    J Bone Miner Res; 2013 May; 28(5):1229-42. PubMed ID: 23239200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcutaneous carbon dioxide application suppresses bone destruction caused by breast cancer metastasis.
    Takemori T; Kawamoto T; Ueha T; Toda M; Morishita M; Kamata E; Fukase N; Hara H; Fujiwara S; Niikura T; Kuroda R; Akisue T
    Oncol Rep; 2018 Oct; 40(4):2079-2087. PubMed ID: 30066936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological evidence for the bone-autonomous contribution of the NFκB/β-catenin axis to breast cancer related osteolysis.
    Marino S; Bishop RT; Logan JG; Mollat P; Idris AI
    Cancer Lett; 2017 Dec; 410():180-190. PubMed ID: 28965856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Zhai ZJ; Li HW; Liu GW; Qu XH; Tian B; Yan W; Lin Z; Tang TT; Qin A; Dai KR
    Br J Pharmacol; 2014 Feb; 171(3):663-75. PubMed ID: 24125472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dihydroartemisinin prevents breast cancer-induced osteolysis via inhibiting both breast caner cells and osteoclasts.
    Feng MX; Hong JX; Wang Q; Fan YY; Yuan CT; Lei XH; Zhu M; Qin A; Chen HX; Hong D
    Sci Rep; 2016 Jan; 6():19074. PubMed ID: 26743690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis.
    Ohshiba T; Miyaura C; Inada M; Ito A
    Br J Cancer; 2003 Apr; 88(8):1318-26. PubMed ID: 12698202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.